Proshares UltraPro NASDAQ Biotechnology
UBIO
UBIO was delisted on the 27th of March, 2020.
6 hedge funds and large institutions have $1.22M invested in Proshares UltraPro NASDAQ Biotechnology in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
5,550% more call options, than puts
Call options by funds: $226K | Put options by funds: $4K
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
102% more capital invested
Capital invested by funds: $603K → $1.22M (+$613K)
50% more funds holding
Funds holding: 4 → 6 (+2)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$615K |
| 2 |
VF
Virtu Financial
New York
|
+$338K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$69.8K |
| 4 |
CG
Cutler Group
San Francisco,
California
|
+$15.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$457K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$166K |
| 3 |
Morgan Stanley
New York
|
-$10.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $646K | +$615K | +23,346 | New |
|
|
VF
2
Virtu Financial
New York
| $355K | +$338K | +12,843 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $73K | +$69.8K | +2,651 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $67K | -$166K | -6,302 | -72% |
|
|
CG
5
Cutler Group
San Francisco,
California
| $47K | +$15.8K | +598 | +53% |
|
|
6
Morgan Stanley
New York
| $28K | -$10.5K | -400 | -29% |
|
|
7
Jane Street
New York
| – | -$457K | -17,347 | Closed |
|
UBIO Hedge Fund Activity: Q1 2017 in Review
6 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Proshares UltraPro NASDAQ Biotechnology (UBIO) for Q1 2017, worth a combined $1.22M — up 102% from $603K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new UBIO positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $615K. The largest seller was Jane Street, exiting entirely with an estimated $457K sold.
- 6 institutional investors held Proshares UltraPro NASDAQ Biotechnology (UBIO) as of Q1 2017, up from 4 in Q4 2016.
- Funds reported $1.22M of Proshares UltraPro NASDAQ Biotechnology stock for Q1 2017, up 102% quarter-over-quarter.
- 3 funds opened new Proshares UltraPro NASDAQ Biotechnology positions in Q1 2017 and 1 closed out, a net change of +2 holders.
- The largest Proshares UltraPro NASDAQ Biotechnology buyer in Q1 2017 was Susquehanna International Group, an estimated $615K added.
- The largest Proshares UltraPro NASDAQ Biotechnology seller in Q1 2017 was Jane Street, an estimated $457K sold.
Based on aggregated 13F filings for Q1 2017.